Reduction in Pruritus Across Indications in Phase 3 Trials of Topical Roflumilast in Patients as Young as 2 Years. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 10, n. 2, p. s766, 2026. DOI: 10.25251/94s3pn30. Disponível em: https://skin.dermsquared.com/skin/article/view/4064. Acesso em: 30 apr. 2026.